Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

NCT07270835 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hemophagocytic Lymphohistiocytosis
B Cell Lymphoma

Interventions

DRUG: Rituximab
DRUG: Zanubrutinib

Sponsor

The First Affiliated Hospital of Soochow University